Harrow Announces Third Quarter 2026 Financial Results

Harrow Health (HROW) reported Q3 GAAP EPS of $0.25, exceeding expectations. Shares rose 14% to $31.52, driven by record revenue and growth in eye-care products.

Harrow reported Q3 revenue of $99.3M, with VEVYE contributing $39.7M (up 35% sequentially). IHEEZO and TRIESENCE unit demand rose 21% and 37% sequentially, respectively. The QUELL study missed its primary endpoint but showed lower pain scores for IHEEZO. Harrow plans to submit a new drug application for G-MELT and is in discussions regarding licensing agreements.

Harrow (HROW) reported Q3 2026 revenue of $99.3M, up 41% sequentially and 39% YoY, with adjusted EBITDA at $21.2M. Key products VEVYE, IHEEZO, and TRIESENCE drove growth. The company reaffirmed FY 2026 revenue guidance of $350M-$365M but lowered adjusted EBITDA outlook. Harrow expanded its product portfolio and commercial infrastructure, acquiring TYRVAYA in October 2026.

Harrow (HROW) completed its acquisition of Tyrvaya, a dry eye treatment, from Viatris. Harrow paid $30M upfront, with up to $70M in milestones. Tyrvaya is FDA-approved and complements Harrow's existing dry eye therapy, Vevye. Harrow expects Tyrvaya to generate over $30M in 2027 revenue.

HARROW, INC. (HROW) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise NASHVILLE, Tenn., October 5, 2026 — Harrow (Nasdaq: HROW), a leading provi

Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.